ArticlePathologica2022

In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.

Caterina Fumagalli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.